English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Review question / Objective: Our study aims to synthesise results from randomised controlled trials to assess the effectiveness and safety of PRP combined with intravitreous ranibizumab for T2PDR. Condition being studied: Diabetic retinopathy (DR) is the most common complication of diabetes mellitus, which will seriously affect the quality of life of patients and bring great burden to patients’ families and society. DR is one of the most important diseases of blindness in people aged 20 to 60 years worldwide. Nearly 15% of diabetic patients with a disease duration of more than 5 years were combined with DR.The prevalence of vision threatening diabetic retinopathy in the United States is 4.4 percent. Worldwide, the prevalence is estimated at 10.2%.At present, the treatment methods for type 2 proliferative diabetic retinopathy (T2PDR), at home and abroad mainly include retinal laser photocoagulation and intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors.

Effectiveness and safety of panretinal photocoagulation combined with intravitreous ranibizumab for patients with type 2 proliferative diabetic retinopathy：A protocol for systematic review and meta-analysis